Home > Dermatology > AAD 2020 > IL-4/IL-13 blocker dupilumab effective in children with severe AD

IL-4/IL-13 blocker dupilumab effective in children with severe AD

The IL-4/IL-13 blocker dupilumab leads to rapid symptom control and itch reduction in children with severe atopic dermatitis (AD), as was demonstrated in the phase 3 LIBERTY AD PEDS study [1].

Previous trials have already shown that dupilumab is effective in adults and adolescents ≥12 years with moderate-to-severe AD inadequately controlled with topical prescription therapies. However, there is also an ongoing medical need for younger children with severe AD. Prolonged use of topical steroids can potentially damage the skin barrier resulting in thinning of the skin. Untreated, moderate-to-severe AD can not only impact a child’s physical development, but can have psychological sequelae, placing a substantial burden on parents and caregivers [2].

The double-blind phase 3 LIBERTY AD PEDS study aimed to assess the efficacy and safety of dupilumab in children with severe AD aged ≥6 to <12 year...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on